IP Library › Granted Patent US 11,780,866
Granted Patent B2
US 11,780,866 · App. 17/032,120 · Granted Oct 10, 2023

Organometallic compound, organic light-emitting device including organometallic compound, and diagnostic composition including organometallic compound

Inventors: Sunyoung Lee (Seoul, KR); Yoonhyun Kwak (Seoul, KR); Juhyun Kim (Seoul, KR); Sangho Park (Anyang-si, KR); Sunghun Lee (Hwaseong-si, KR); Jeoungin Yi (Seoul, KR)
Assignee: SAMSUNG ELECTRONICS CO., LTD.
C07F15/0033H10K85/342C09K11/06C09K2211/1425C09K2211/1433C09K2211/1466C09K2211/185H10K50/11H10K2101/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,780,866
App. No.
17/032,120
Granted
Oct 10, 2023
Kind
B2
Abstract

Provided are an organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound: M(L 1 ) n1 (L 2 ) n2   Formula 1 wherein, in Formula 1, M, L 1 , L 2 , n1 and n2 may each be understood by referring to the descriptions thereof provided herein.

Claims (81)

1. An organometallic compound represented by Formula 1:

M(L 1 ) n1 (L 2 ) n2   Formula 1

wherein the organometallic compound represented by Formula 1 comprises a group represented by —Si(Q 3 )(Q 4 )(Q 5 ), a group represented by —Ge(Q 3 )(Q 4 )(Q 5 ), or any combination thereof,

wherein, in Formula 1,

M is a transition metal,

L 1 is a ligand represented by Formula 2,

L 2 is a ligand represented by Formula 3,

n1 and n2 are each 1 or 2, and the sum of n1 and n2 is 3,

L 1 is different from L 2 ,

wherein, in Formulae 2 and 3,

Y 11 is N, and Y 12 is C,

ring CY 1 and ring CY 11 are each independently a C 1 -C 30 heterocyclic group,

ring CY 2 and ring CY 12 are each independently a C 5 -C 30 carbocyclic group or a C 1 -C 30 heterocyclic group,

X 21 is O, S, Se, N(R 28 ), C(R 28 )(R 29 ), or Si(R 28 )(R 29 ),

R 1 , R 2 , R 28 , R 29 , Z 1 , and Z 2 are each independently deuterium, —F, —Cl, —Br, —I, —SF 5 , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C 1 -C 60 alkyl group, a substituted or unsubstituted C 2 -C 60 alkenyl group, a substituted or unsubstituted C 2 -C 60 alkynyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted C 6 -C 30 unsaturated carbocyclic group, a substituted or unsubstituted C 2 -C 30 unsaturated heterocyclic group, —N(Q 1 )(Q 2 ), —Si(Q 3 )(Q 4 )(Q 5 ), —Ge(Q 3 )(Q 4 )(Q 5 ), —B(Q 6 )(Q 7 ), —P(═O)(Q 8 )(Q 9 ), or —P(Q 8 )(Q 9 ), provided that R 2 is not —Si(Q 3 )(Q 4 )(Q 5 ),

i) a1 is 0, and a2 is 1 or 2,

ii) a1 is 1 or 2, and a2 is 0, or

iii) a1 is 1 or 2, and a2 is 1 or 2;

d1 is an integer from 0 to 10,

wherein, when a1 is 2 or greater, at least two R 1 (s) are identical to or different from each other; when a2 is 2 or greater, at least two R 2 (s) are identical to or different from each other; and when d1 is 2 or greater, at least two Z 1 (s) are identical to or different from each other,

d2 is an integer from 1 to 10, wherein, when d2 is 2 or greater, at least two Z 2 (s) are identical to or different from each other,

at least two selected from a plurality of R 1 (s) are optionally linked to form a C 5 -C 30 carbocyclic group unsubstituted or substituted with at least one R 10a or a C 1 -C 30 heterocyclic group unsubstituted or substituted with at least one R 10a ,

at least two selected from a plurality of R 2 (s) are optionally linked to form a C 5 -C 30 carbocyclic group unsubstituted or substituted with at least one R 10a or a C 1 -C 30 heterocyclic group unsubstituted or substituted with at least one R 10a ,

at least two selected from a plurality of Z 1 (s) are optionally linked to form a C 5 -C 30 carbocyclic group unsubstituted or substituted with at least one R 10a or a C 1 -C 30 heterocyclic group unsubstituted or substituted with at least one R 10a ,

at least two selected from a plurality of Z 2 (s) are optionally linked to form a C 5 -C 30 carbocyclic group unsubstituted or substituted with at least one R 10a or a C 1 -C 30 heterocyclic group unsubstituted or substituted with at least one R 10a ,

at least two selected from R 1 (s), R 2 (s), Z 1 (s), and Z 2 (s) are optionally linked to form a C 5 -C 30 carbocyclic group unsubstituted or substituted with at least one R 10a or a C 1 -C 30 heterocyclic group unsubstituted or substituted with at least one R 10a ,

R 10a is understood by referring to the description of R 1 provided herein,

* and *′ each indicate a binding site to M in Formula 1, and

a substituent of the substituted C 1 -C 60 alkyl group, the substituted C 2 -C 60 alkenyl group, the substituted C 2 -C 60 alkynyl group, the substituted C 1 -C 60 alkoxy group, the substituted C 6 -C 30 unsaturated carbocyclic group, and the substituted C 2 -C 30 unsaturated heterocyclic group is:

deuterium, —F, —Cl, —Br, —I, —CD 3 , —CD 2 H, —CF 3 , —CF 2 H, —CFH 2 , a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, or a C 1 -C 60 alkoxy group;

a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, or a C 1 -C 60 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD 3 , —CD 2 H, —CDH 2 , —CF 3 , —CF 2 H, —CFH 2 , a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 6 -C 30 unsaturated carbocyclic group, a C 2 -C 30 unsaturated heterocyclic group, —N(Q 11 )(Q 12 ), —Si(Q 13 )(Q 14 )(Q 15 ), —Ge(Q 13 )(Q 14 )(Q 15 ), —B(Q 16 )(Q 17 ), —P(═O)(Q 18 )(Q 19 ), —P(Q 18 )(Q 19 ), or any combination thereof;

a C 6 -C 30 unsaturated carbocyclic group or a C 2 -C 30 unsaturated heterocyclic group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD 3 , —CD 2 H, —CDH 2 , —CF 3 , —CFH 2 , —CFH 2 , a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, a C 1 -C 60 alkoxy group, a C 6 -C 30 unsaturated carbocyclic group, a C 2 -C 30 unsaturated heterocyclic group, —N(Q 21 )(Q 22 ), —Si(Q 23 )(Q 24 )(Q 25 ), —Ge(Q 23 )(Q 24 )(Q 25 ), —B(Q 26 )(Q 27 ), —P(═O)(Q 28 )(Q 29 ), —P(Q 28 )(Q 29 ), or any combination thereof;

—N(Q 31 )(Q 32 ), —Si(Q 33 )(Q 34 )(Q 35 ), —Ge(Q 33 )(Q 34 )(Q 35 ), —B(Q 36 )(Q 37 ), —P(═O)(Q 38 )(Q 39 ), or —P(Q 38 )(Q 39 ); or

any combination thereof,

wherein Q 1 to Q 9 , Q 11 to Q 19 , Q 21 to Q 29 , and Q 31 to Q 39 are each independently: hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; an amidino group; a hydrazine group; a hydrazone group; a carboxylic acid group or a salt thereof a sulfonic acid group or a salt thereof; a phosphoric acid group or a salt thereof; a C 1 -C 60 alkyl group unsubstituted or substituted with deuterium, a C 1 -C 60 alkyl group, a C 6 -C 60 aryl group, or any combination thereof a C 2 -C 60 alkenyl group; a C 2 -C 60 alkynyl group; a C 1 -C 60 alkoxy group; or a C 6 -C 30 unsaturated carbocyclic group or C 2 -C 30 unsaturated heterocyclic group, each unsubstituted or substituted with deuterium, a C 1 -C 60 alkyl group, a C 6 -C 60 aryl group, or any combination thereof.

2. The organometallic compound of claim 1 , wherein M is Ir.

3. The organometallic compound of claim 1 , wherein

ring CY 1 and ring CY 11 are each independently a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a 5,6,7,8-tetrahydroisoquinoline group, or a 5,6,7,8-tetrahydroquinoline group, and

ring CY 2 and ring CY 12 are each independently a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a 1,2,3,4-tetrahydronaphthalene group, a thiophene group, a furan group, an indole group, a borole group, a silole group, a germole group, a phosphole group, a selenophene group, a benzoborole group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a dibenzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-one group, a dibenzothiophene 5,5-dioxide group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a 5,6,7,8-tetrahydroisoquinoline group, or a 5,6,7,8-tetrahydroquinoline group.

4. The organometallic compound of claim 1 , wherein X 21 is O or S.

5. The organometallic compound of claim 1 , wherein R 1 , R 2 , R 28 , R 29 , Z 1 , and Z 2 are each independently:

deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, —SF 5 , a C 1 -C 20 alkyl group, a C 1 -C 20 alkenyl group, or a C 1 -C 20 alkoxy group;

a C 1 -C 20 alkyl group, a C 1 -C 20 alkenyl group, or a C 1 -C 20 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD 3 , —CD 2 H, —CDH 2 , —CF 3 , —CF 2 H, —CFH 2 , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 10 alkyl group, a phenyl group, a (C 1 -C 20 alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof;

a phenyl group, a (C 1 -C 20 alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, or an azadibenzothiophenyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD 3 , —CD 2 H, —CDH 2 , —CF 3 , —CF 2 H, —CFH 2 , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 20 alkyl group, a deuterated C 2 -C 20 alkyl group, a C 1 -C 20 alkoxy group, a phenyl group, a (C 1 -C 20 alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, or any combination thereof; or

—N(Q 1 )(Q 2 ), —Si(Q 3 )(Q 4 )(Q 5 ), —Ge(Q 3 )(Q 4 )(Q 5 ), —B(Q 6 )(Q 7 ), —P(═O)(Q 8 )(Q 9 ), or —P(Q 8 )(Q 9 ), provided that R 2 is not —Si(Q 3 )(Q 4 )(Q 5 ),

wherein Q 1 to Q 9 are each independently:

deuterium, —F, —CH 3 , —CD 3 , —CD 2 H, —CDH 2 , —CH 2 CH 3 , —CH 2 CD 3 , —CH 2 CD 2 H, —CH 2 CDH 2 , —CHDCH 3 , —CHDCD 2 H, —CHDCDH 2 , —CHDCD 3 , —CD 2 CD 3 , —CD 2 CD 2 H, —CD 2 CDH 2 , —CF 3 , —CF 2 H, —CFH 2 , —CH 2 CF 3 , —CH 2 CF 2 H, —CH 2 CFH 2 , —CHFCH 3 , —CHFCF 2 H, —CHFCFH 2 , —CHFCF 3 , —CF 2 CF 3 , —CF 2 CF 2 H, or —CF 2 CFH 2 ; or

an n-propyl group, an iso-propyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, a sec-isopentyl group, a phenyl group, a biphenyl group, or a naphthyl group, each unsubstituted or substituted with deuterium, —F, a C 1 -C 10 alkyl group, a phenyl group, or any combination thereof.

6. The organometallic compound of claim 1 , wherein

d1 is 0, 1, or 2, and

d2 is 1, 2, 3, or 4.

7. The organometallic compound of claim 1 comprising at least one deuterium.

8. The organometallic compound of claim 1 , wherein ring CY 1 in Formula 2 is represented by one of Formulae CY1-1 to CY1-19:

wherein, in Formulae CY1-1 to CY1-19, *′ indicates a binding site to M in Formula 1, and *″ indicates a binding site to an adjacent benzo group.

9. The organometallic compound of claim 1 , wherein a group represented by

in Formula 2 is represented by one of Formulae CY2-1 to CY2-6:

wherein, in Formulae CY2-1 to CY2-6, X 21 and ring CY 2 are each understood by referring to the descriptions thereof in claim 1 , * indicates a binding site to M in Formula 1, and *″ indicates a binding site to ring CY 1 in Formula 2.

10. The organometallic compound of claim 1 , wherein a group represented by

in Formula 2 is represented by one of Formulae CY2(1) to CY2(22):

wherein, in Formulae CY2(1) to CY2(22), X 21 is understood by referring to the description thereof in claim 1 , R 21 to R 26 are each understood by referring to the description of R 2 in claim 1 , * indicates a binding site to M in Formula 1, and *″ indicates a binding site to ring CY 1 in Formula 2.

11. The organometallic compound of claim 1 , wherein a group represented by

in Formula 3 is represented by one of Formulae CY11(1) to CY11(18):

wherein, in Formulae CY11(1) to CY11(18), Y 12 is understood by referring to the description thereof in claim 1 , Z 11 to Z 14 are each understood by referring to the description of Z 1 in claim 1 , * indicates a binding site to M in Formula 1, and *″ indicates a binding site to an adjacent atom in Formula 3.

12. The organometallic compound of claim 1 , wherein a group represented by

in Formula 3 is represented by one of Formulae CY12(1) to CY12(17):

wherein, in Formulae CY12(1) to CY12(17), Y 12 is understood by referring to the description thereof in claim 1 , Z 21 to Z 24 are each understood by referring to the description of Z 2 in claim 1 , *′ indicates a binding site to M in Formula 1, and *″ indicates a binding site to an adjacent atom in Formula 3.

13. The organometallic compound of claim 1 , wherein the organometallic compound is of Compounds 5, 7 to 9, 13 to 14, 22, 173, 175 to 176, 179, and 181:

14. An organic light-emitting device comprising:

a first electrode;

a second electrode; and

an organic layer disposed between the first electrode and the second electrode and comprising an emission layer; and

wherein, the organic layer comprises at least one organometallic compound of claim 1 .

15. The organic light-emitting device of claim 14 , wherein

the first electrode is an anode,

the second electrode is a cathode, and

the organic layer further comprises a hole transport region disposed between the first electrode and the emission layer and an electron transport region disposed between the emission layer and the second electrode,

the hole transport region comprises a hole injection layer, a hole transport layer, an electron blocking layer, a buffer layer, or any combination thereof, and

the electron transport region comprises a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

16. The organic light-emitting device of claim 14 , wherein the emission layer comprises the organometallic compound.

17. The organic light-emitting device of claim 16 , wherein the emission layer further comprises a host in an amount greater than an amount of the organometallic compound.

18. A diagnostic composition comprising one of the organometallic compound of claim 1 .

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR: JUNGIN LEE PREVIOUSLY RECORDED ON REEL 053890 FRAME 0749. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Nov 5, 2020
From: LEE, SUNYOUNG; KWAK, YOONHYUN; KIM, JUHYUN; PARK, SANGHO; LEEM, SUNGHUN; YI, JEOUNGIN
To: SAMSUNG ELECTRONICS CO., LTD.
Reel/Frame 054314/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2020
From: LEE, SUNYOUNG; KWAK, YOONHYUN; KIM, JUHYUN; PARK, SANGHO; LEE, SUNGHUN; LEE, JUNGIN
To: SAMSUNG ELECTRONICS CO., LTD.
Reel/Frame 053890/0749 →
Priority Claims (1)
KR 10-2019-0152230 · Nov 25, 2019 · national
Continuity (1)
Related Publication 20210155647A1 · May 27, 2021